Roche asks, Ventana says no...again

Roche is starting to look like that annoying guy who won't take no for an answer--the company keeps asking Ventana Medical Systems if it wants to join up, and Ventana keeps refusing. Is Ventana playing hard to get, or should Roche just give up?

Here's the evidence: Roche says only 63,541 Ventana shares have been tendered, about two-tenths of one percent of the 34 million outstanding. Understandable, since the tender offer was for $75, and shares closed yesterday at over $83. But Roche extended its offer once again, at the same price, through Nov. 1. Ventana haughtily rejected the third advance, saying it's worth much more than $75 a share. It's clear that Ventana's no cheap date. We'll see if Roche sweetens the deal.

- read the news release on Roche's extension
- read Ventana's response to the extension of Roche's offer

Related Articles:
Roche wins round in battle for Ventana. Report
Roche note opens door to a higher Ventana bid. Report
Ventana spurns Roche's $3B hostile takeover bid. Report
Ventana shares soar on hostile $3B bid. Report
Roche shakes up R&D, eyes new buyouts. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.